Zn-based physiometacomposite nanoparticles: distribution, tolerance, imaging, and antiviral and anticancer activity
The aim of this study was to investigate the distribution, tolerance, and anticancer and antiviral activity of Zn-based physiometacomposites (PMCs). Manganese, iron, nickel and cobalt-doped ZnO, ZnS or ZnSe were synthesized. Cell uptake, distribution into 3D culture and mice, and biochemical and chemotherapeutic activity were studied by fluorescence/bioluminescence, confocal microscopy, flow cytometry, viability, antitumor and virus titer assays. Luminescence and inductively coupled plasma mass spectrometry analysis showed that nanoparticle distribution was liver >spleen >kidney >lung >brain, without tissue or blood pathology. Photophysical characterization as tissue probes and LL37 peptide, antisense oligomer or aptamer delivery targeting RAS/Ras binding domain (RBD) was investigated. Treatment at 25 μg/ml for 48 h showed ≥98-99% cell viability, 3D organoid uptake, 3-log inhibition of β-Galactosidase and porcine reproductive respiratory virus infection. Data support the preclinical development of PMCs for imaging and delivery targeting cancer and infectious disease.
Physics, Astronomy, and Materials Science
anticancer activity, antisense oligomer delivery, antiviral activity, aptamer delivery, nanomedicine, peptide delivery
DeLong, Robert K., Ryan Swanson, Megan C. Niederwerder, Pratiksha Khanal, Santosh Aryal, Ramesh Marasini, Majid Jaberi-Douraki et al. "Zn-based physiometacomposite nanoparticles: distribution, tolerance, imaging, and antiviral and anticancer activity." Nanomedicine 16, no. 21 (2021).